U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

AVASIMIBE

MORE DETAILS

  28LQ20T5RC

Status:
Investigational
Source:
INN:avasimibe
Source URL:
https://tripod.nih.gov/npc/#Download
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Acyl coenzyme A:cholesterol acyltransferase 1
15
Cytochrome P450 2C9
50
Cytochrome P450 1A2
73
Cytochrome P450 2C19
51
Acyl coenzyme A:cholesterol acyltransferase 2
4
Conditions:
Atherosclerosis
76
Hyperlipidemia
82
Avasimibe (CI 1011) is a potent ACAT (Acyl-CoA:cholesterol acyltransferase) inhibitor. Avasimibe inhibits both ACAT1 and ACAT2 isoforms. Avasimibe was in development by Parke-Davis (now Pfizer) in the US for the treatment of atherosclerosis and hyperlipidaemia. Avasimibe was in phase III studies and more than 1300 patients had been treated for up to one year, however, in October 2003, Pfizer announced that development had been discontinued.

AVASIMIBE SODIUM

MORE DETAILS

  32035QP3VQ

Status:
Investigational
Source:
INN:avasimibe
Source URL:
https://tripod.nih.gov/npc/#Download
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Acyl coenzyme A:cholesterol acyltransferase 1
15
Cytochrome P450 2C9
50
Cytochrome P450 1A2
73
Cytochrome P450 2C19
51
Acyl coenzyme A:cholesterol acyltransferase 2
4
Conditions:
Atherosclerosis
76
Hyperlipidemia
82
Avasimibe (CI 1011) is a potent ACAT (Acyl-CoA:cholesterol acyltransferase) inhibitor. Avasimibe inhibits both ACAT1 and ACAT2 isoforms. Avasimibe was in development by Parke-Davis (now Pfizer) in the US for the treatment of atherosclerosis and hyperlipidaemia. Avasimibe was in phase III studies and more than 1300 patients had been treated for up to one year, however, in October 2003, Pfizer announced that development had been discontinued.
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966